Ascendis Pharma A/S (ASND) Q4 2023 Earnings Results

Ascendis Pharma A/S Misses on Revenue, Stock Down 1.1%

Ascendis Pharma reported a larger-than-expected loss per share, beating EPS estimates but not providing revenue figures. The stock reacted negatively, declining by 1.1%. Investors may be cautious due to the lack of revenue information and forward guidance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.66	N/A	+23.11%
Revenue	—	N/A	—

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

Ascendis Pharma A/S Misses on Revenue, Stock Down 1.1%

Key numbers

Management commentary

Ascendis Pharma A/S

More earnings this week

Ascendis Pharma A/S Misses on Revenue, Stock Down 1.1%

Key numbers

Management commentary